Investor Presentation • Aug 30, 2018
Investor Presentation
Open in ViewerOpens in native device viewer
BerGenBio to Present at the 20th Annual Global Investment Conference in New York City September 4-6, 2018
Bergen, Norway, August 30th, 2018 - BerGenBio ASA (OSE:BGBIO), announces that
Richard Godfrey, CEO of BerGenBio, is scheduled to present an overview of the
Company's business and ongoing phase II clinical development programme with its
first-in-class selective AXL inhibitor bemcentinib at the 20th Annual Rodman &
Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co.,
LLC, on September 5th 2018 at 9:35 AM (Eastern Time).
The presentation will be webcast live. To access presentation slides and
webcast, please visit www.bergenbio.com/investors/presentations/. The webcast
replay will remain available for 90 days following the live presentation.
- END -
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
advanced and aggressive cancers.
The company's proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme. Ongoing clinical trials are investigating bemcentinib in multiple
solid and haematological tumours, in combination with current and emerging
therapies (including immunotherapies, targeted therapies and chemotherapy), and
as a single agent.
In parallel, BerGenBio is developing companion diagnostics test to identify
patient populations most likely to benefit from bemcentinib; this is expected to
facilitate more efficient registration trials and support a precision medicine
-based commercialisation strategy.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). www.bergenbio.com
About AXL
AXL kinase is cell membrane receptor and an essential mediator of the biological
mechanisms that drive aggressive and life-threatening diseases. In cancer, AXL
drives tumour survival, treatment resistance and spread, as well as suppressing
the body's immune response to tumours. AXL expression has been established as a
negative prognostic factor in many cancers. AXL inhibitors, therefore, have
potential value at the centre of cancer combination therapy, addressing
significant unmet medical needs and multiple high-value market opportunities.
Forward-Looking Statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.
Contacts
Richard Godfrey
CEO, BerGenBio ASA
+47 917 86 304
Rune Skeie
CFO, BerGenBio ASA
+47 917 86 513
Media Relations in Norway
Jan Petter Stiff, Crux Advisers
+47 995 13 891
International Media Relations
David Dible, Mark Swallow, Marine Perrier, Citigate Dewe Rogerson
+44 207 638 9571
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.